About this condition
GERD — Genetic Susceptibility
Gastroesophageal reflux disease (GERD) affects approximately 20% of Western populations. Twin studies estimate 30-40% heritability. GWAS have identified susceptibility loci near FOXF1 (16q24.1), GDF7 (2p24.1), MHC region (6p21), and CCND1 (11q13) — genes involved in esophageal development, immune regulation, and epithelial integrity.
Barrett's esophagus (the precancerous GERD complication) has distinct genetic risk factors. The CRTC1 locus (19p13.11) and FOXF1 locus are specifically associated with Barrett's and esophageal adenocarcinoma risk. Individuals with these susceptibility variants plus chronic GERD may benefit from earlier endoscopic surveillance for Barrett's detection.
CYP2C19 is the primary PPI metabolizing enzyme. Ultra-rapid metabolizers (CYP2C19 *17/*17, ~5-10% of Europeans) may have inadequate acid suppression on standard PPI doses — requiring dose escalation or switch to vonoprazan (potassium-competitive acid blocker, not CYP2C19 dependent). Poor metabolizers (*2/*2, *2/*3) have higher PPI drug levels and may need dose reduction. CYP2C19 genotyping optimizes PPI therapy.
If your PPI 'doesn't work,' it might be your genes, not the drug. CYP2C19 ultra-rapid metabolizers break down omeprazole too fast — they need dose adjustment or a different acid blocker.
- Gene locus
- CYP2C19 (10q23.33), FOXF1 (16q24.1), GDF7 (2p24.1), CRTC1 (19p13.11), CCND1 (11q13.3)
